Skip to main content


Page 34 of 39

  1. MicroRNAs (miRNAs) are emerging as a novel class of non-coding RNA molecules that regulate gene expression at a post-transcriptional level. More than 1000 miRNAs have been identified in human cells to date, an...

    Authors: Yu-Meng Sun, Kang-Yu Lin and Yue-Qin Chen
    Citation: Journal of Hematology & Oncology 2013 6:6
  2. Tissue factor (TF) pathway inhibitor-1 (TFPI) is expressed in several malignant tissues- and cell lines and we recently reported that it possesses anti-tumor effects in breast cancer cells, indicating a biolog...

    Authors: Benedicte Stavik, Mari Tinholt, Marit Sletten, Grethe Skretting, Per Morten Sandset and Nina Iversen
    Citation: Journal of Hematology & Oncology 2013 6:5
  3. To assess if intensity-modulated radiotherapy (IMRT) can possibly lead to improved local control and lower incidence of vision impairment/blindness in comparison to non-IMRT techniques when treating sinonasal ...

    Authors: Alexander Chi, Nam P Nguyen, William Tse, Gill Sobremonte, Patrick Concannon and Angela Zhu
    Citation: Journal of Hematology & Oncology 2013 6:4
  4. Notch1 is a potent regulator known to play an oncogenic role in many malignancies including T-cell acute lymphoblastic leukemia (T-ALL). Tumor hypoxia and increased hypoxia-inducible factor-1α (HIF-1α) activit...

    Authors: Jie Zou, Peng Li, Fei Lu, Na Liu, Jianjian Dai, Jingjing Ye, Xun Qu, Xiulian Sun, Daoxin Ma, Jino Park and Chunyan Ji
    Citation: Journal of Hematology & Oncology 2013 6:3
  5. Despite advances in understanding of clinical, genetic, and molecular aspects of multiple myeloma (MM) and availability of more effective therapies, MM remains incurable. The autologous-allogeneic (auto-allo) ...

    Authors: Mohamed A Kharfan-Dabaja, Mehdi Hamadani, Tea Reljic, Taiga Nishihori, William Bensinger, Benjamin Djulbegovic and Ambuj Kumar
    Citation: Journal of Hematology & Oncology 2013 6:2
  6. Antibody-dependent cellular cytotoxicity (ADCC) is a major mechanism of action of therapeutic monoclonal antibodies (mAbs) such as cetuximab, rituximab and trastuzumab. Fc gamma receptors (FcgR) on human white...

    Authors: James D Mellor, Michael P Brown, Helen R Irving, John R Zalcberg and Alexander Dobrovic
    Citation: Journal of Hematology & Oncology 2013 6:1
  7. A previous study has demonstrated a significant decrease in the TCRζ gene expression level in chronic myeloid leukemia (CML); thus, we further investigated the expression of TCRζ-regulating factors, the distri...

    Authors: Xianfeng Zha, Xiaojuan Yan, Qi Shen, Yuping Zhang, Xiuli Wu, Shaohua Chen, Bo Li, Lijian Yang, Suxia Geng, Jianyu Weng, Xin Du and Yangqiu Li
    Citation: Journal of Hematology & Oncology 2012 5:74
  8. Stem cell factor (SCF) activates hematopoietic stem cell (HSC) self-renewal and is being used to stimulate the ex vivo expansion of HSCs. The mechanism by which SCF supports expansion of HSCs remains poorly un...

    Authors: Jie Fan, Xinxin Ding and Yongping Jiang
    Citation: Journal of Hematology & Oncology 2012 5:73
  9. Lenalidomide treatment in myelodysplastic syndrome (MDS) may lead to thrombocytopenia and dose reductions/delays. This study evaluated the safety and tolerability of the thrombopoietin mimetic romiplostim and ...

    Authors: Eunice S Wang, Roger M Lyons, Richard A Larson, Sunil Gandhi, Delong Liu, Carmen Matei, Bart Scott, Kuolung Hu and Allen S Yang
    Citation: Journal of Hematology & Oncology 2012 5:71
  10. Promotion of endothelial normalization restores tumor oxygenation and obstructs tumor cells invasion, intravasation, and metastasis. We therefore investigated whether a vasoactive drug, tanshinone IIA, could i...

    Authors: Wen-Quan Wang, Liang Liu, Hui-Chuan Sun, Yan-Ling Fu, Hua-Xiang Xu, Zong-Tao Chai, Qiang-Bo Zhang, Ling-Qun Kong, Xiao-Dong Zhu, Lu Lu, Zheng-Gang Ren and Zhao-You Tang
    Citation: Journal of Hematology & Oncology 2012 5:69
  11. Pancreatic cancer (PC) is a lethal malignancy primarily driven by activated Kras mutations and characterized by the deregulation of several genes including mucins. Previous studies on mucins have identified their...

    Authors: Satyanarayana Rachagani, María P Torres, Sushil Kumar, Dhanya Haridas, Michael Baine, Muzafar A Macha, Sukhwinder Kaur, Moorthy P Ponnusamy, Parama Dey, Parthasarathy Seshacharyulu, Sonny L Johansson, Maneesh Jain, Kay-Uwe Wagner and Surinder K Batra
    Citation: Journal of Hematology & Oncology 2012 5:68
  12. The randomized phase 3 LYM3001 trial in relapsed follicular lymphoma (FL) demonstrated higher overall (ORR) and complete response (CR) rates and prolonged progression-free survival (PFS) with bortezomib-rituxi...

    Authors: Pier Luigi Zinzani, Nuriet K Khuageva, Huaqing Wang, Bernardo Garicochea, Jan Walewski, Achiel Van Hoof, Pierre Soubeyran, Dolores Caballero, Rena Buckstein, Dixie-Lee Esseltine, Panteli Theocharous, Christopher Enny, Eugene Zhu, Yusri A Elsayed and Bertrand Coiffier
    Citation: Journal of Hematology & Oncology 2012 5:67
  13. The discovery of miRNAs has revolutionized the way we examine the genome, RNA products, and the regulation of transcription and translation. Their ability to modulate protein expression through mRNA degradatio...

    Authors: Anthony Virtue, Hong Wang and Xiao-feng Yang
    Citation: Journal of Hematology & Oncology 2012 5:66
  14. von Willebrand factor (vWF) is a multimeric glycoprotein essential for hemostasis after vascular injury, which modulates platelet-surface and platelet–platelet interactions by linking platelet receptors to the...

    Authors: Hailong Yuan, Ning Deng, Songmei Zhang, Yange Cao, Qiong Wang, Xin Liu and Qing Zhang
    Citation: Journal of Hematology & Oncology 2012 5:65
  15. Rituximab (RTX), a monoclonal antibody (mAb) against CD20, has been widely used for lymphoma therapy. RTX in combination with cyclophosphamide /doxorubicin /vincristine /prednisone (R-CHOP) remains the standar...

    Authors: Shundong Cang, Nikhil Mukhi, Kemeng Wang and Delong Liu
    Citation: Journal of Hematology & Oncology 2012 5:64
  16. In the first line treatment of non-small cell lung cancer (NSCLC), several clinical trials have shown that not all NSCLC patients can benefit from treatment with tyrosine kinase inhibitors (TKIs) than receivin...

    Authors: Chongrui Xu, Qing Zhou and Yi-long Wu
    Citation: Journal of Hematology & Oncology 2012 5:62
  17. The recent findings brought the necessity of testing the mutational status of a series of genes which had been already identified as responsible for melanomas development and progression, such as BRAF, CKIT an...

    Authors: Giovanni Ponti, Aldo Tomasi and Giovanni Pellacani
    Citation: Journal of Hematology & Oncology 2012 5:60
  18. Patients with many types of autoimmune diseases (AIDs) are at an increased risk of cancer, which may depend on underlying dysregulation of the immune system or treatment. We systematically analyzed myeloma ris...

    Authors: Kari Hemminki, Xiangdong Liu, Asta Försti, Jianguang Ji, Jan Sundquist and Kristina Sundquist
    Citation: Journal of Hematology & Oncology 2012 5:59
  19. Colorectal Cancer (CRC) is one of the leading causes of death worldwide. Numerous cellular events, including deregulated expression of microRNAs (miRNAs), specifically the family of miR-34 consisting of miR-34...

    Authors: Sanchita Roy, Edi Levi, Adhip PN Majumdar and Fazlul H Sarkar
    Citation: Journal of Hematology & Oncology 2012 5:58
  20. Lymphomas frequently retain wild-type (wt) p53 function but overexpress HDM2, thereby compromising p53 activity. Therefore, lymphoma is a suitable model for studying the therapeutic value of disrupting the HDM...

    Authors: Angela M Sosin, Angelika M Burger, Aisha Siddiqi, Judith Abrams, Ramzi M Mohammad and Ayad M Al-Katib
    Citation: Journal of Hematology & Oncology 2012 5:57
  21. Recent studies have been reported that angiogenesis suppression may play a role in developing bisphosphonate-related osteonecrosis of the jaw (B-ONJ). According to these evidence we evaluated the role of VEGF ...

    Authors: Bruno Vincenzi, Andrea Napolitano, Alice Zoccoli, Michele Iuliani, Francesco Pantano, Nicola Papapietro, Vincenzo Denaro, Daniele Santini and Giuseppe Tonini
    Citation: Journal of Hematology & Oncology 2012 5:56
  22. Despite the combinations of chemotherapy with monoclonal antibodies have further improved response rates, chronic lymphocytic leukemia (CLL) remains an incurable disease with an extremely variable course. This...

    Authors: Kang Lu and Xin Wang
    Citation: Journal of Hematology & Oncology 2012 5:55
  23. Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin Lymphoma comprising of greater than 30% of adult non-Hodgkin Lymphomas. DLBCL represents a diverse set of lymphomas, defined as diff...

    Authors: Carlos A Tirado, Weina Chen, Rolando García, Kelly A Kohlman and Nagesh Rao
    Citation: Journal of Hematology & Oncology 2012 5:54
  24. Arsenic Trioxide (ATO) is effective in about 20% of patients with myelodysplasia (MDS); its mechanisms of action have already been evaluated in vitro, but the in vivo activity is still not fully understood. Si...

    Authors: Sara Galimberti, Francesca Guerrini, Flavia Salvi, Iacopo Petrini, Daniela Gioia, Emanuela Messa, Giuseppe A Palumbo, Daniela Cilloni, Mario Petrini and Alessandro Levis
    Citation: Journal of Hematology & Oncology 2012 5:53
  25. Epidermal growth factor receptor gene copy number (EGFR GCN) has been heavily investigated as a potential predictive biomarker for the treatment of metastatic colorectal cancer (mCRC) with anti-EGFR monoclonal an...

    Authors: Zu-Yao Yang, Wei-Xi Shen, Xue-Feng Hu, Da-Yong Zheng, Xin-Yin Wu, Ya-Fang Huang, Jin-Zhang Chen, Chen Mao and Jin-Ling Tang
    Citation: Journal of Hematology & Oncology 2012 5:52
  26. The precise mechanism of action for rituximab (R) is not fully elucidated. Besides antibody-dependent cellular cytotoxicity (ADCC), complements may also play an important role in the clinical response to ritux...

    Authors: Xuan Jin, Huirong Ding, Ning Ding, Zhiying Fu, Yuqin Song and Jun Zhu
    Citation: Journal of Hematology & Oncology 2012 5:51
  27. The objective of this study was to identify prognostic factors for survival in patients with primary diffuse large B-cell lymphoma (DLBCL) of the adrenal gland.

    Authors: Yu Ri Kim, Jin Seok Kim, Yoo Hong Min, Dok Hyun Yoon, Ho-Jin Shin, Yeung-Chul Mun, Yong Park, Young Rok Do, Seong Hyun Jeong, Joon Seong Park, Sung Yong Oh, Suee Lee, Eun Kyung Park, Joung-Soon Jang, Won-Sik Lee, Hwe-Won Lee…
    Citation: Journal of Hematology & Oncology 2012 5:49
  28. The molecular pathogenesis underlying the primary myelofibrosis (PMF) progression to acute myeloid leukemia (AML) is still not well defined. The involvement of microRNA (miRNA) is actually helping to shed ligh...

    Authors: Francesco Albano, Luisa Anelli, Antonella Zagaria, Nicoletta Coccaro, Paola Casieri, Angela Minervini and Giorgina Specchia
    Citation: Journal of Hematology & Oncology 2012 5:48
  29. The mechanisms responsible for chemoresistance in patients with refractory classical Hodgkin lymphoma (CHL) are unknown. ATP-binding cassette (ABC) transporters confer multidrug resistance in various cancers and

    Authors: Wesley Greaves, Lianchun Xiao, Beatriz Sanchez-Espiridion, Kranthi Kunkalla, Kunal S Dave, Cynthia S Liang, Rajesh R Singh, Anas Younes, L Jeffrey Medeiros and Francisco Vega
    Citation: Journal of Hematology & Oncology 2012 5:47
  30. Intensified conditioning regimens (increasing the intensity of standard myeloablative conditioning) for hematological malignancies in allogeneic hematopoietic stem cell transplantation (allo-HSCT) could reduce...

    Authors: Li Xuan, Fen Huang, Zhiping Fan, Hongsheng Zhou, Xian Zhang, Guopan Yu, Yu Zhang, Can Liu, Jing Sun and Qifa Liu
    Citation: Journal of Hematology & Oncology 2012 5:46
  31. Although GATA1 is one of the most extensively studied haematopoietic transcription factors little is currently known about the physiological functions of its naturally occurring isoforms GATA1s and GATA1FL in hum...

    Authors: Christina Halsey, Marie Docherty, Mhairi McNeill, Derek Gilchrist, Michelle Le Brocq, Brenda Gibson and Gerard Graham
    Citation: Journal of Hematology & Oncology 2012 5:45
  32. Therapy-related myeloid neoplasms (t-MN), including myelodysplastic syndromes and acute myeloid leukemia (t-MDS and t-AML) are associated to clinical and biologic unfavorable prognostic features, including hig...

    Authors: Luana Fianchi, Marianna Criscuolo, Monia Lunghi, Gianluca Gaidano, Massimo Breccia, Alessandro Levis, Carlo Finelli, Valeria Santini, Pellegrino Musto, Esther N Oliva, Pietro Leoni, Antonietta Aloe Spiriti, Francesco D’Alò, Stefan Hohaus, Livio Pagano, Giuseppe Leone…
    Citation: Journal of Hematology & Oncology 2012 5:44
  33. Splenomegaly is a common sign of primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (post-PV MF), and post-essential thrombocythemia myelofibrosis (post-ET MF) that is associated with bothersome...

    Authors: Jasleen Randhawa, Alen Ostojic, Radovan Vrhovac, Ehab Atallah and Srdan Verstovsek
    Citation: Journal of Hematology & Oncology 2012 5:43
  34. Acute lymphoblastic leukemia (ALL) is the most frequently-occurring malignant neoplasm in children, but the pathogenesis of the disease remains unclear. In a microarray assay using samples from 100 children wi...

    Authors: Limin Zou, Han Zhang, Chaohao Du, Xiao Liu, Shanshan Zhu, Wei Zhang, Zhigang Li, Chao Gao, Xiaoxi Zhao, Mei Mei, Shilai Bao and Huyong Zheng
    Citation: Journal of Hematology & Oncology 2012 5:42
  35. This study was aimed to investigate the significance of 18F-FDG PET/CT in secondary hemophagocytic lymphohistiocytosis (sHLH) patients. A total of 18 patients received 18F-FDG PET/CT scan at initial diagnosis. Al...

    Authors: Li-Juan Zhang, Ji Xu, Peng Liu, Chong-Yang Ding, Jian-Yong Li, Hong-Xia Qiu and Su-Jiang Zhang
    Citation: Journal of Hematology & Oncology 2012 5:40
  36. Gain-of-function mutations of tyrosine kinase FLT3 are frequently found in acute myeloid leukemia (AML). This has made FLT3 an important marker for disease diagnosis and a highly attractive target for therapeu...

    Authors: Yun Chen, Yao Guo, Jiayu Han, Wanting Tina Ho, Shibo Li, Xueqi Fu and Zhizhuang Joe Zhao
    Citation: Journal of Hematology & Oncology 2012 5:39
  37. Systemic anaplastic large cell lymphoma (S-ALCL) is a rare disease with a highly variable prognosis and no standard chemotherapy regimen. Anaplastic lymphoma kinase (ALK) has been reported as an important prog...

    Authors: Yan-Fang Wang, Yan-Li Yang, Zi-Fen Gao, Chun-Ju Zhou, Xylina Gregg, Yun-Fei Shi, Jing Wang, Xiao-Feng Yang and Xiao-Yan Ke
    Citation: Journal of Hematology & Oncology 2012 5:38
  38. Hepatocellular carcinoma (HCC) is one of the most common malignant tumors occurring mainly in patients with chronic liver disease. Detection of early HCC is critically important for treatment of these patients.

    Authors: Yantong Guo, Jingming Zhao, Jingtao Bi, Quan Wu, Xin Wang and Quanyou Lai
    Citation: Journal of Hematology & Oncology 2012 5:37
  39. Men with metastatic castration-resistant prostate cancer (mCRPC) carry poor prognosis despite the use of docetaxel-based regimens which has modest survival benefit shown by randomized clinical trials. Signific...

    Authors: Xuan Huang, Cindy H Chau and William D Figg
    Citation: Journal of Hematology & Oncology 2012 5:35
  40. Multiple immunotherapy approaches have improved adaptive anti-tumor immune responses in patients with early stage disease; however, results have been less dramatic when treating patients with late stage diseas...

    Authors: Jarrod D Predina, Veena Kapoor, Brendan F Judy, Guanjun Cheng, Zvi Gregory Fridlender, Steven M Albelda and Sunil Singhal
    Citation: Journal of Hematology & Oncology 2012 5:34
  41. Autologous stem cell transplantation (ASCT) is the gold standard therapy for suitable multiple myeloma (MM) patients after induction with high dose therapy. To date, the evidence of a reliable marker of progno...

    Authors: Cristina Guimarães, Rui Bergantim, Renata Ramalho, Nuno Couto, João T Guimarães and Fernanda Trigo
    Citation: Journal of Hematology & Oncology 2012 5:33
  42. Myelodysplastic syndrome (MDS) is a clonal hematopoietic stem cell disorder of elderly people. Cardiac dysfunction is a marker of grim prognosis in MDS. We evaluated cardiac dysfunction of MDS patients with or...

    Authors: Cláudio César Monteiro de Castro, Carlos Bellini Gondim Gomes, Manoel Ricardo Alves Martins, Juliana Cordeiro de Sousa, Silvia MM Magalhaes and Ronald F Pinheiro
    Citation: Journal of Hematology & Oncology 2012 5:30

Annual Journal Metrics

  • Citation Impact 2023
    Journal Impact Factor: 29.5
    5-year Journal Impact Factor: 26.9
    Source Normalized Impact per Paper (SNIP): 4.489
    SCImago Journal Rank (SJR): 7.522

    Speed 2023
    Submission to first editorial decision (median days): 4
    Submission to acceptance (median days): 59

    Usage 2023
    Downloads: 3,173,795
    Altmetric mentions: 2,671

Institutional membership

Visit the membership page to check if your institution is a member and learn how you could save on article-processing charges (APCs).

Funding your APC

​​​​​​​Open access funding and policy support by SpringerOpen​​

​​​​We offer a free open access support service to make it easier for you to discover and apply for article-processing charge (APC) funding. Learn more here